KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Common Equity (2016 - 2025)

Quest Diagnostics' Common Equity history spans 17 years, with the latest figure at $7.2 billion for Q4 2025.

  • For Q4 2025, Common Equity rose 5.78% year-over-year to $7.2 billion; the TTM value through Dec 2025 reached $7.2 billion, up 5.78%, while the annual FY2025 figure was $7.2 billion, 5.78% up from the prior year.
  • Common Equity for Q4 2025 was $7.2 billion at Quest Diagnostics, down from $7.3 billion in the prior quarter.
  • Across five years, Common Equity topped out at $7.3 billion in Q3 2025 and bottomed at $5.9 billion in Q4 2022.
  • The 5-year median for Common Equity is $6.5 billion (2023), against an average of $6.6 billion.
  • The largest annual shift saw Common Equity rose 19.06% in 2021 before it dropped 8.53% in 2022.
  • A 5-year view of Common Equity shows it stood at $6.5 billion in 2021, then decreased by 8.53% to $5.9 billion in 2022, then increased by 6.95% to $6.3 billion in 2023, then grew by 6.87% to $6.8 billion in 2024, then rose by 5.78% to $7.2 billion in 2025.
  • Per Business Quant, the three most recent readings for DGX's Common Equity are $7.2 billion (Q4 2025), $7.3 billion (Q3 2025), and $7.3 billion (Q2 2025).